Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p53MVA and Pembrolizumab in Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT03113487Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- May 2019
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of p53MVA and pembrolizumab in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by City of Hope. Primary endpoint: Objective Response Rate at 24 months. Started May 2019; status: active, not recruiting.
02
Drugs
p53MVApembrolizumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03113487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113487.